Jose V J, Zechariah T U, George P, Jonathan V
Department of Cardiology, Christian Medical College Hospital, Vellore.
Indian Heart J. 1999 Mar-Apr;51(2):183-5.
The effects of growth hormone in six patients with dilated cardiomyopathy were evaluated in this study. The patients were studied at baseline, after six months of therapy and at six months after stopping the treatment. They were given two units of growth hormone on alternate days by subcutaneous injection. There was marked improvement in the symptomatic class with treatment (NYHA class 3.4 +/- 0.5 vs 2 +/- 0; p = 0.04). There was also significant increase in the inteventricular septal wall thickness (6.4 +/- 1.5 mm vs 10.4 +/- 0.5 mm; p = 0.04). Left ventricular posterior wall thickness also increased significantly (7.2 +/- 1.3 mm vs 10.2 +/- 0.8 mm; p = 0.04). These changes were partially reversed by the end of six months of treatment but the symptomatic status of these patients was better than before. The administration of growth hormone for six months in patients with dilated cardiomyopathy results in significant improvement in the symptomatic class, which could be considered as an additional line of management in patients with heart failure in dilated cardiomyopathy.
本研究评估了生长激素对6例扩张型心肌病患者的影响。在基线期、治疗6个月后以及停止治疗6个月后对患者进行研究。他们每隔一天皮下注射两单位生长激素。治疗后症状分级有显著改善（纽约心脏协会分级从3.4±0.5降至2±0；p = 0.04）。室间隔厚度也显著增加（从6.4±1.5毫米增至10.4±0.5毫米；p = 0.04）。左心室后壁厚度也显著增加（从7.2±1.3毫米增至10.2±0.8毫米；p = 0.04）。这些变化在治疗6个月末部分逆转，但这些患者的症状状态比之前有所改善。对扩张型心肌病患者给予6个月生长激素治疗可使症状分级显著改善，这可被视为扩张型心肌病心力衰竭患者的一种额外治疗方法。
